Evidence map›Paper›PMID 36548785›Full record

ArticleToxins2022

Cationic PLGA Nanoparticle Formulations as Biocompatible Immunoadjuvant for Serum Production and Immune Response against

Emanuell Dos Santos-Silva, Manoela Torres-Rêgo, Fiamma Gláucia-Silva, Renata Carvalho Feitosa, Ariane Ferreira Lacerda, Hugo Alexandre de Oliveira Rocha, Matheus de Freitas Fernandes-Pedrosa, Arnóbio Antônio da Silva-Júnior

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxins, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Emanuell Dos Santos-SilvaLaboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte (UFRN), Natal-RN 59072-970, Brazil.ORCID 0000-0002-9849-4496
Manoela Torres-RêgoLaboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte (UFRN), Natal-RN 59072-970, Brazil.ORCID 0000-0002-8535-1533
Fiamma Gláucia-SilvaLaboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte (UFRN), Natal-RN 59072-970, Brazil.
Renata Carvalho FeitosaLaboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte (UFRN), Natal-RN 59072-970, Brazil.ORCID 0000-0001-8509-5245
Ariane Ferreira LacerdaLaboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte (UFRN), Natal-RN 59072-970, Brazil.
Hugo Alexandre de Oliveira RochaPrograma de Pós-Graduação em Bioquímica, Universidade Federal do Rio Grande do Norte, Natal-RN 59072-970, Brazil.
Matheus de Freitas Fernandes-PedrosaLaboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte (UFRN), Natal-RN 59072-970, Brazil.ORCID 0000-0003-4221-9580
Arnóbio Antônio da Silva-JúniorLaboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte (UFRN), Natal-RN 59072-970, Brazil.ORCID 0000-0002-7516-1787
Universidade Federal do Rio Grande do Norte · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Snakebite envenoming represents a worldwide public health issue. Suitable technologies have been investigated for encapsulated recombinant or native proteins capable of inducing an effective and long-lasting adaptive immune response. Nanoparticles are colloidal dispersions that have been used as drug delivery systems for bioactive biological compounds. Venom-loaded nanoparticles modulate the protein release and activate the immune response to produce specific antibodies. In this study, biocompatible cationic nanoparticles with

Indexed as

BothropsCrotalid VenomsNanoparticlesAdjuvants, ImmunologicAluminum HydroxideAnimalsImmunityProteinsAdjuvants, ImmunologicAluminum HydroxideCrotalid VenomsProteinsBothrops jararacaimmunoadjuvantsnanobiotechnologyPLGA nanoparticles

Identifiers

PMID36548785
PMCPMC9786128
OpenAlexW4311963382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.